利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

65 条记录 (耗时 0.018 秒)

    The use of activated t-lymphocytes for preparing a pharmaceutical composition for the treatment of AIDS
    2.
    发明授权
    The use of activated t-lymphocytes for preparing a pharmaceutical composition for the treatment of AIDS 失效
    用于制备用于治疗AIDS的药物组合物使用活化的T淋巴细胞的。

    公开(公告)号：EP0260714B1

    公开(公告)日：1994-06-29

    申请号：EP87113709.7

    申请日：1987-09-18

    申请人： ONCOGEN LIMITED PARTNERSHIP

    发明人： Hu, Shiu-Lok, Ph. D. ,  Zarling, Joyce

    IPC分类号： A61K39/21 ,  A61K45/00

    CPC分类号： A61K39/21 ,  A61K39/12 ,  A61K2039/5158 ,  C12N2740/16034

    摘要： The invention relates to the use of activated T lymphocytes at a dosage effective in transferring cell mediated imunity against AIDS virus infected cells in vivo, in which: (a) the activated T lymphocytes are specific for an epitope of the AIDS virus and histocompatible with the patient; and (b) the activated T lymphocytes are capable of mediating AIDS virus specific T cell immunity as measured by either of the following assays: (i) a cytotoxicity assay in which the activated T lymphocytes are incubated with the patient's radiolabelled target cells infected with AIDS virus, the release of radiolabel being an indication of lysis of the infected target cells; and (ii) a stimulation assay which measures the ability of the activated T lymphocytes to proliferate and/or produce a lymphokine in response to stimulation with an epitope of the AIDS virus in vitro for preparing a pharmaceutical composition for the treatment of AIDS.

    Antigens of human non-small lung carcinoma
    4.
    发明公开
    Antigens of human non-small lung carcinoma 失效
    荨麻醇“非小”肺癌。

    公开(公告)号：EP0566066A1

    公开(公告)日：1993-10-20

    申请号：EP93106003.2

    申请日：1985-10-30

    申请人： ONCOGEN LIMITED PARTNERSHIP

    发明人： Hellstrom, Ingegerd ,  Brown, Joseph Patrick ,  Hellstrom, Karl Erik ,  Horn, Diane ,  Linsley, Peter

    IPC分类号： C07K15/06 ,  A61K39/00

    CPC分类号： C07K14/4748 ,  A61K39/00 ,  C07K16/3023 ,  Y10S530/864 ,  Y10S530/866

    摘要： An antigenic composition purified from normal human serum or the culture medium of human non-small cell lung carcinoma cells comprising a non-denatured glycosylated Form I L3 protein, said protein having the following N-terminal amino acid sequence :
    a molecular weight of about 94,000 daltons as determined by SDS polyacrylamide gel electrophoresis under reducing conditions, and N-linked glycoside residues in which the terminal residues of the N-linked glycoside residues are sialic acid residues.

    摘要翻译： 从正常人血清或人非小细胞肺癌细胞培养基中纯化的抗原组合物，其包含非变性糖基化形式I L3蛋白，所述蛋白质具有以下N-末端氨基酸序列：分子量 在还原条件下通过SDS聚丙烯酰胺凝胶电泳测定的约94,000道尔顿，以及N-连接的糖苷残基，其中N-连接的糖苷残基的末端残基是唾液酸残基。

    Normal human growth regulatory receptor for TGF beta
    9.
    发明公开
    Normal human growth regulatory receptor for TGF beta 失效
    正常人TGF-Rezeptor，das Wachstum bei Menschen regelnd。

    公开(公告)号：EP0369861A2

    公开(公告)日：1990-05-23

    申请号：EP89403084.0

    申请日：1989-11-08

    申请人： ONCOGEN LIMITED PARTNERSHIP

    发明人： Lioubin, Mario N. ,  Brown, Thomas J. ,  Purchio, Anthony F.

    IPC分类号： C07K15/12 ,  C07K15/14 ,  C12N15/00 ,  C07K3/20

    CPC分类号： C07K14/71

    摘要： Type III TGF-β receptor is identified in and purified from normal human embryonic palatal mesenchyme (HEPM) cells and the purified product characterized structurally and functionally. HEPM cells were found to express high levels of the type III TGF-β receptor and were found to significantly down-regulate two classes of TGF-β receptor binding site. Purification of the type III TGF-β receptor from solubilized HEPM cell membranes by affinity chromatography yielded a biologically active protein of about 205 kd which specifically binds both the recombinant and natural forms of TGF-β1 and TGF-β2, with affinity dissociation constants in the picomolar range.

    摘要翻译： III型TGF-β受体在正常人胚胎腭裂间质（HEPM）细胞中鉴定并纯化，纯化的产物在结构和功能上表征。 发现HEPM细胞表达高水平的III型TGF-β受体，并被发现显着下调两类TGF-β受体结合位点。 通过亲和层析从溶解的HEPM细胞膜中纯化III型TGF-β受体，得到约205kd的生物活性蛋白，其特异性结合重组和天然形式的TGF-β1和TGF-β2，具有亲和解离常数 在皮摩摩范围内。

    Antibody heteroconjugates for use in regulation of lymphocyte activity
    10.
    发明公开
    Antibody heteroconjugates for use in regulation of lymphocyte activity 失效
    Antikörper-Heterokonjugate zur Regulation derLymphozytenaktivität。

    公开(公告)号：EP0336379A2

    公开(公告)日：1989-10-11

    申请号：EP89105907.3

    申请日：1989-04-04

    申请人： ONCOGEN LIMITED PARTNERSHIP

    发明人： Ledbetter, Jeffrey A.

    IPC分类号： A61K39/395 ,  A61K39/42 ,  A61K39/39

    CPC分类号： C07K16/2809 ,  C07K16/2806 ,  C07K16/2812 ,  C07K16/2815 ,  C07K16/2818 ,  C07K16/289 ,  C07K16/2896 ,  C07K16/468 ,  C07K2317/31 ,  C07K2317/73

    摘要： The present invention relates to novel antibody heteroconjugates and their use in the enhancement or inhibition of T or B lymphocytes. The heteroconjugate are comprised of at least two molecules cross-linked to each other, each antibody being reactive with a different cell surface antigen on the same cell. The heteroconjugates appear to act by binding to lymphocytes via the interaction of the antibodies of the heteroconjugate with their respective cell surface antigens and bringing those antigens into physical proximity to each other, resulting in enhanced or reduced activation and function of the lymphocytes. The heteroconjugates, methods and compositions of this invention are therefore useful in the regulation of lymphocyte function, resulting in the improvement of cellular immune responses in various disease states.

    摘要翻译： 本发明涉及新型抗体异源结合物及其在增强或抑制T淋巴细胞或B淋巴细胞中的用途。 异源偶联物由至少两个彼此交联的分子组成，每个抗体与相同细胞上的不同细胞表面抗原具有反应性。 异源偶联似乎通过与异源偶联物的抗体与其各自的细胞表面抗原的相互作用结合淋巴细胞而起作用，并使这些抗原彼此物理上接近，导致淋巴细胞的活化和功能增强或降低。 因此，本发明的异源结合物，方法和组合物可用于调节淋巴细胞功能，导致改善各种疾病状态下的细胞免疫应答。